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Chronic inflammation, which may be caused by a Africans. 4Using electronmlcroscopy, elementary bod- 
chronic infection, is similar to the early process that ies resembling chlamydial organisms were found in 
results in the formation of atherosclerotic plaque)The macrophages from the lipid rich core of the plaque 
evidence, however, that supports the hypothesis that and in the smooth muscle cells, but not in the normal 
there may be a link between chronic infection and adjacent issues or in tissues from patients without 
atherosclerosis has, until recently, been circumspect, atherosclerosis. These organisms were subsequently 
In 1978 it was reported that experimental infection of confirmed to be C. pneumomae using immuno- 
germ-free chickens with an avian herpesvirus resulted cytochemistry and the polymerase chain reaction, s 
in an arterial disease that was similar to human athero- To date, a number of studies have established the 
sclerosis. Subsequently, associations between human presence of C. pneumoniae in human arterial tissues on 
atherosclerotic occlusive disease and Gram-negative the basis of demonstrating chlamydial DNA, antigens, 
bacteria (e.g. Helicobacter pylori, Chlamydia pneumoniae), or elementary bodies. Infection was considered to be 
viruses (e.g. cytomegalovirus), and with clinical present in a little more than half the atheromatous 
markers of chronic infection (e.g. chronic periodontal lesions examined (52%) compared to only 5% of control 
disease) have been reported. Of these, C. pneumoniae tissues (weighted odds ratio +10). 6 The organisms, 
has emerged as the strongest contender m the search which have been found in plaque of coronary, carotid 
for an infectious agent in the pathogenesis of athero- and peripheral arteries and m the walls of aortic 
sclerosis, aneurysms, have been demonstrated to be viable 7and 
Chlamy&a pneumoniae, which was previously called have been cultured. 8 
the TWAR agent, was first isolated from young adults The smooth muscle cells, that have been dem- 
with acute respiratory infections in Seattle in 1986 2 It is onstrated to be infected with the organism, show signs 
an intracellular Gram-negative bacterium, transmitted of cellular damage, with rupture and fragmentation 
presumably byrespiratoryaerosol transmission, which of tile cell. This results in release of organisms and 
may survive within human macrophages for many cellular content, which may be the stimulus for the 
years. Serological data suggests that C. pneumomae is macrophage r action, resulting in the development of
one of the most prevalent infections, with antibodies the foam cell and subsequently of the plaque. 9
against he orgamsm present in 60-70% of the popu- 
lation in tropical countries. It causes between five and 
10% of commumty acquired pneumonia, bronchitis 
and sinusitis) Serological evidence 
The potential role of C. pneumoniae in the aetiology 
of atherosclerosis is based on the following evidence: The presence of a viable infective agent in athero- 
sclerotic lesions raises the question of a causative 
Chlamydia pneumoniae found m plaque role. The odds ratio of patients having atherosclerotlc 
vascular disease in the presence of antibodies to C. 
Chlamydia pneumoniae was first identified in ath- pneumomae is at least two or greater, with some 
erosclerotic lesions of coronary arteries from South studies demonstrating an increasing odds raho in 
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the presence of increasing titres. 6The methods used sclerosis, it remains unclear how C. pneumoniae enters 
to detect antibodies in the reported studies are, atheromatous plaque and whether it has a direct causal 
however, variable and some of these are associated role in the atherosclerotic process. It has been sug- 
with poor reproducibility. Nonetheless, the general gested that the organisms can replicate in alveolar 
consistency of the above findings in over 2700 cases macrophages and after pulmonary infecton may gain 
supports the existence of some real association access to the circulation to spread by monocytes and 
between C. pneumoniae and atherosclerotic vascular macrophages. This is supported by the organism hav- 
disease. This notion is given further weight by ing been found in multiple extrapulmonary sites, m- 
the observation of Gupta et al. who screened 220 cluding arthritic jomts and cerebrospinal fluid. 
consecutive male survivors of a myocardial infarct The postulated consequences of organism uptake 
for IgG antibodies against C. pneumoniae, l° Patients by macrophages m the vessel wall include: 9'm4 
with positive antibody titres had a four-fold increased The organism may simply reside in the macrophage 
risk of developing adverse cardiovascular events without causing any deleterious effects and any 
over a mean follow-up period of 18 months compared association may be purely coincidental. 
to the group that was antibody negative. The Chronic macrophage infection may contribute to 
incidence of events was also increased with increasing local inflammation and development of the plaque. 
antibody titres. The presence of serum antibodies The infection may induce direct chronic endothelial 
does not, however, necessarily indicate the persistence or smooth muscle cell damage. 
of active infection, or persistent exposure of arteries As C. pneumoniae titres have been shown to have a 
to injury, weak correlation with procoagulants such as fib- 
rinogen concentrations, infection may lead to an 
increased risk of thrombosis. 
Eradwatwn of Chlamy&a pneumomae 
If C. pneumoniae does have a causative role, then Conclusion 
eradication of the organism can be expected to arrest 
the advance of the atherosclerotic lesions. Chlamydia The evidence suggesting an association between 
pneumoniae is sensitive to treatment with tetracyclines atherosclerosis and C. pneumoniae is substantial, but 
and macrolides. Two studies have been published there is presently little direct evidence ndorsing the 
evaluating macrolides in patients with atherosclerotic hypothesis that atheroscleroszs is caused by, or is made 
vascular disease. In a double-blind, randomised, worse by, the presence of this organism in established 
placebo-controlled study of 202 patients with unstable plaque. The conclusive proof that such a chronic in- 
angina or with non-Q-wave myocardial mfarction, the fection has a direct role in the pathogeneszs of athero- 
ROXIS pilot study reported a statistically significant sclerosis will only come from further prospective 
reduction in all end points (severe recurrent myo- eradication studies evaluating a wide spectrum of 
cardial ischaemla, myocardial infarction, ischaemic atherosclerotlc vascular diseases. Several such studies 
death) at I month in patients given roxithromycin for are presently being performed. The question of 
30 days (9/100 placebo group vs. 2/102 roxithromycin whether C. pneumomae is an innocent bystander or 
group; p = 0.036). I1 In the study by Gupta et at. patients whether it is a vicious assassin 15cannot presently be 
with persistently high antibody titres (>_ 1/65, n = 48) answered with certainty, and the potential of treating 
were randomised to receive azithromycin (for 3 days) atherosclerotic vascular diseases with antibiotics is as 
or placebo. I° The likelihood of developing adverse yet not a reality. 
cardiovascular events in those patients receiving active 
therapy was found to be similar to that observed in 
antibody-negative patients. This observation was not References 
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